176 related articles for article (PubMed ID: 24971463)
1. Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.
Bergantin E; Quarta C; Nanni C; Fanti S; Pession A; Cantelli-Forti G; Tonelli R; Hrelia P
Cancer Biol Ther; 2014 Sep; 15(9):1219-25. PubMed ID: 24971463
[TBL] [Abstract][Full Text] [Related]
2. TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells.
Jin CY; Molagoda IMN; Karunarathne WAHM; Kang SH; Park C; Kim GY; Choi YH
Toxicol Appl Pharmacol; 2018 Aug; 352():132-141. PubMed ID: 29792947
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.
Matsui TA; Sowa Y; Yoshida T; Murata H; Horinaka M; Wakada M; Nakanishi R; Sakabe T; Kubo T; Sakai T
Carcinogenesis; 2006 Sep; 27(9):1768-77. PubMed ID: 16571651
[TBL] [Abstract][Full Text] [Related]
5. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
6. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
Seitz G; Warmann SW; Vokuhl CO; Heitmann H; Treuner C; Leuschner I; Fuchs J
Pediatr Surg Int; 2007 May; 23(5):431-9. PubMed ID: 17211591
[TBL] [Abstract][Full Text] [Related]
7. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
8. Sulforaphane blocks hypoxia-mediated resistance to TRAIL-induced tumor cell death.
Jeong JK; Moon MH; Seo JS; Seol JW; Lee YJ; Park SY
Mol Med Rep; 2011; 4(2):325-30. PubMed ID: 21468572
[TBL] [Abstract][Full Text] [Related]
9. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
[TBL] [Abstract][Full Text] [Related]
10. Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced apoptosis.
Lee DH; Kim DW; Lee HC; Lee JH; Lee TH
Biochem Biophys Res Commun; 2014 Apr; 446(4):815-21. PubMed ID: 24491546
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5.
Kim H; Kim EH; Eom YW; Kim WH; Kwon TK; Lee SJ; Choi KS
Cancer Res; 2006 Feb; 66(3):1740-50. PubMed ID: 16452234
[TBL] [Abstract][Full Text] [Related]
12. Phenethyl isothiocyanate enhances TRAIL-induced apoptosis in oral cancer cells and xenografts.
Yeh CC; Ko HH; Hsieh YP; Wu KJ; Kuo MY; Deng YT
Clin Oral Investig; 2016 Dec; 20(9):2343-2352. PubMed ID: 26822174
[TBL] [Abstract][Full Text] [Related]
13. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
[TBL] [Abstract][Full Text] [Related]
15. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
16. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
Wang S; Ren W; Liu J; Lahat G; Torres K; Lopez G; Lazar AJ; Hayes-Jordan A; Liu K; Bankson J; Hazle JD; Lev D
Clin Cancer Res; 2010 May; 16(9):2591-604. PubMed ID: 20406839
[TBL] [Abstract][Full Text] [Related]
17. PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.
Zeng FY; Cui J; Liu L; Chen T
Cancer Lett; 2009 Nov; 284(2):157-64. PubMed ID: 19442434
[TBL] [Abstract][Full Text] [Related]
18. 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.
Stolfi C; Caruso R; Franzè E; Rizzo A; Rotondi A; Monteleone I; Fantini MC; Pallone F; Monteleone G
Mol Cancer Ther; 2011 Oct; 10(10):1969-81. PubMed ID: 21817114
[TBL] [Abstract][Full Text] [Related]
19. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
20. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
